TNFa-inhibition in the treatment of rheumatoid arthritis
The introduction of tumor-necrosis-factor-alpha (TNFa) blocking agents is one of the milestones in the therapy of rheumatoid arthritis (RA). Edited by Larry Moreland and Paul Emery, experts in rheumatological disease, TNFa-Inhibition in the Treatment of Rheumatoid Arthritis charts the history and de...
Saved in:
Other Authors: | , |
---|---|
Format: | Book |
Language: | English |
Published: |
London New York Independence, KY
Martin Dunitz Fulfilment Center, Taylor & Francis
2003
|
Subjects: | |
Online Access: | Click Here to View Status and Holdings. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000nam a2200000#i 4501 | ||
---|---|---|---|
001 | wils-322742 | ||
005 | 20231882654 | ||
008 | 230208t2003 -UK a# #001 deng D | ||
020 | # | # | |a 9781841841564 |q paperback |
020 | # | # | |a 1841841560 |q paperback |
040 | # | # | |a UKM |d UiTM |e rda |
041 | 0 | # | |a English |
060 | 0 | 0 | |a WE 346 |
090 | 0 | 0 | |a WE346 |b T626 2003 |
245 | 0 | 0 | |a TNFa-inhibition in the treatment of rheumatoid arthritis |c edited by Larry W. Moreland, Paul Emery |
264 | # | 1 | |a London |a New York |a Independence, KY |b Martin Dunitz |b Fulfilment Center, Taylor & Francis |c 2003 |
264 | # | 4 | |c ©2003 |
300 | # | # | |a viii, 180 pages |b illustrations |c 21 cm |
336 | # | # | |a text |b txt |2 rdacontent |
337 | # | # | |a unmediated |b n |2 rdamedia |
338 | # | # | |a volume |b nc |2 rdacarrier |
504 | # | # | |a Includes bibliographical references and index |
520 | # | # | |a The introduction of tumor-necrosis-factor-alpha (TNFa) blocking agents is one of the milestones in the therapy of rheumatoid arthritis (RA). Edited by Larry Moreland and Paul Emery, experts in rheumatological disease, TNFa-Inhibition in the Treatment of Rheumatoid Arthritis charts the history and development of the concept of TNFa inhibition. The authors document TNFa from its discovery to its now well-documented clinical applications in the treatment of patients with RA. They compare and contrast practical management issues concerning the use of these agents both in the US and UK/Europe. The book is a practical and accessible source containing the most recent information in this field |
650 | 1 | 2 | |a Arthritis, Rheumatoid |x drug therapy |
650 | 1 | 2 | |a Tumor Necrosis Factor Inhibitors |
650 | 2 | 2 | |a Antibodies, Monoclonal |x therapeutic use |
650 | 2 | 2 | |a Antirheumatic Agents |x therapeutic use |
650 | 2 | 2 | |a Receptors, Tumor Necrosis Factor |x therapeutic use |
700 | 1 | # | |a Moreland, Larry W. |e editor |
700 | 1 | # | |a Emery, Paul |e editor |
856 | 4 | 0 | |z Click Here to View Status and Holdings. |u https://opac.uitm.edu.my/opac/detailsPage/detailsHome.jsp?tid=322742 |
964 | # | # | |c BOK |d 01 |
998 | # | # | |a 00264#1a006.2.2||00264#1a002.8.2||00264#1a002.8.2||00264#1b006.2.2||00264#1b002.8.4||00300##a006.2.2||00300##b006.2.2||00300##c006.2.2||00520##a006.2.2||00520##b006.2.2|| |